Cargando…
Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer
PURPOSE: Adoptively transferred, ex vivo expanded multi-antigen-targeted T cells (multiTAA-T) represent a new, potentially effective, and nontoxic therapeutic approach for patients with breast cancer (BC). In this first-in-human trial, we investigated the safety and clinical effects of administering...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290161/ https://www.ncbi.nlm.nih.gov/pubmed/35860837 http://dx.doi.org/10.1177/17588359221107113 |
_version_ | 1784748829127475200 |
---|---|
author | Hoyos, Valentina Vasileiou, Spyridoula Kuvalekar, Manik Watanabe, Ayumi Tzannou, Ifigeneia Velazquez, Yovana French-Kim, Matthew Leung, Wingchi Lulla, Suhasini Robertson, Catherine Foreman, Claudette Wang, Tao Bulsara, Shaun Lapteva, Natalia Grilley, Bambi Ellis, Matthew Osborne, Charles Kent Coscio, Angela Nangia, Julie Heslop, Helen E. Rooney, Cliona M. Vera, Juan F. Lulla, Premal Rimawi, Mothaffar Leen, Ann M. |
author_facet | Hoyos, Valentina Vasileiou, Spyridoula Kuvalekar, Manik Watanabe, Ayumi Tzannou, Ifigeneia Velazquez, Yovana French-Kim, Matthew Leung, Wingchi Lulla, Suhasini Robertson, Catherine Foreman, Claudette Wang, Tao Bulsara, Shaun Lapteva, Natalia Grilley, Bambi Ellis, Matthew Osborne, Charles Kent Coscio, Angela Nangia, Julie Heslop, Helen E. Rooney, Cliona M. Vera, Juan F. Lulla, Premal Rimawi, Mothaffar Leen, Ann M. |
author_sort | Hoyos, Valentina |
collection | PubMed |
description | PURPOSE: Adoptively transferred, ex vivo expanded multi-antigen-targeted T cells (multiTAA-T) represent a new, potentially effective, and nontoxic therapeutic approach for patients with breast cancer (BC). In this first-in-human trial, we investigated the safety and clinical effects of administering multiTAA T cells targeting the tumor-expressed antigens, Survivin, NY-ESO-1, MAGE-A4, SSX2, and PRAME, to patients with relapsed/refractory/metastatic BC. MATERIALS AND METHODS: MultiTAA T-cell products were generated from the peripheral blood of heavily pre-treated patients with metastatic or locally recurrent unresectable BC of all subtypes and infused at a fixed dose level of 2 × 10(7)/m(2). Patients received two infusions of cells 4 weeks apart and safety and clinical activity were determined. Cells were administered in an outpatient setting and without prior lymphodepleting chemotherapy. RESULTS: All patients had estrogen receptor/progesterone receptor positive BC, with one patient also having human epidermal growth factor receptor 2-positive. There were no treatment-related toxicities and the infusions were well tolerated. Of the 10 heavily pre-treated patients enrolled and infused with multiTAA T cells, nine had disease progression while one patient with 10 lines of prior therapies experienced prolonged (5 months) disease stabilization that was associated with the in vivo expansion and persistence of T cells directed against the targeted antigens. Furthermore, antigen spreading and the endogenous activation of T cells directed against a spectrum of non-targeted tumor antigens were observed in 7/10 patients post-multiTAA infusion. CONCLUSION: MultiTAA T cells were well tolerated and induced disease stabilization in a patient with refractory BC. This was associated with in vivo T-cell expansion, persistence, and antigen spreading. Future directions of this approach may include additional strategies to enhance the therapeutic benefit of multiTAA T cells in patients with BC. |
format | Online Article Text |
id | pubmed-9290161 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-92901612022-07-19 Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer Hoyos, Valentina Vasileiou, Spyridoula Kuvalekar, Manik Watanabe, Ayumi Tzannou, Ifigeneia Velazquez, Yovana French-Kim, Matthew Leung, Wingchi Lulla, Suhasini Robertson, Catherine Foreman, Claudette Wang, Tao Bulsara, Shaun Lapteva, Natalia Grilley, Bambi Ellis, Matthew Osborne, Charles Kent Coscio, Angela Nangia, Julie Heslop, Helen E. Rooney, Cliona M. Vera, Juan F. Lulla, Premal Rimawi, Mothaffar Leen, Ann M. Ther Adv Med Oncol Original Research PURPOSE: Adoptively transferred, ex vivo expanded multi-antigen-targeted T cells (multiTAA-T) represent a new, potentially effective, and nontoxic therapeutic approach for patients with breast cancer (BC). In this first-in-human trial, we investigated the safety and clinical effects of administering multiTAA T cells targeting the tumor-expressed antigens, Survivin, NY-ESO-1, MAGE-A4, SSX2, and PRAME, to patients with relapsed/refractory/metastatic BC. MATERIALS AND METHODS: MultiTAA T-cell products were generated from the peripheral blood of heavily pre-treated patients with metastatic or locally recurrent unresectable BC of all subtypes and infused at a fixed dose level of 2 × 10(7)/m(2). Patients received two infusions of cells 4 weeks apart and safety and clinical activity were determined. Cells were administered in an outpatient setting and without prior lymphodepleting chemotherapy. RESULTS: All patients had estrogen receptor/progesterone receptor positive BC, with one patient also having human epidermal growth factor receptor 2-positive. There were no treatment-related toxicities and the infusions were well tolerated. Of the 10 heavily pre-treated patients enrolled and infused with multiTAA T cells, nine had disease progression while one patient with 10 lines of prior therapies experienced prolonged (5 months) disease stabilization that was associated with the in vivo expansion and persistence of T cells directed against the targeted antigens. Furthermore, antigen spreading and the endogenous activation of T cells directed against a spectrum of non-targeted tumor antigens were observed in 7/10 patients post-multiTAA infusion. CONCLUSION: MultiTAA T cells were well tolerated and induced disease stabilization in a patient with refractory BC. This was associated with in vivo T-cell expansion, persistence, and antigen spreading. Future directions of this approach may include additional strategies to enhance the therapeutic benefit of multiTAA T cells in patients with BC. SAGE Publications 2022-07-15 /pmc/articles/PMC9290161/ /pubmed/35860837 http://dx.doi.org/10.1177/17588359221107113 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Hoyos, Valentina Vasileiou, Spyridoula Kuvalekar, Manik Watanabe, Ayumi Tzannou, Ifigeneia Velazquez, Yovana French-Kim, Matthew Leung, Wingchi Lulla, Suhasini Robertson, Catherine Foreman, Claudette Wang, Tao Bulsara, Shaun Lapteva, Natalia Grilley, Bambi Ellis, Matthew Osborne, Charles Kent Coscio, Angela Nangia, Julie Heslop, Helen E. Rooney, Cliona M. Vera, Juan F. Lulla, Premal Rimawi, Mothaffar Leen, Ann M. Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer |
title | Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer |
title_full | Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer |
title_fullStr | Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer |
title_full_unstemmed | Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer |
title_short | Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer |
title_sort | multi-antigen-targeted t-cell therapy to treat patients with relapsed/refractory breast cancer |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290161/ https://www.ncbi.nlm.nih.gov/pubmed/35860837 http://dx.doi.org/10.1177/17588359221107113 |
work_keys_str_mv | AT hoyosvalentina multiantigentargetedtcelltherapytotreatpatientswithrelapsedrefractorybreastcancer AT vasileiouspyridoula multiantigentargetedtcelltherapytotreatpatientswithrelapsedrefractorybreastcancer AT kuvalekarmanik multiantigentargetedtcelltherapytotreatpatientswithrelapsedrefractorybreastcancer AT watanabeayumi multiantigentargetedtcelltherapytotreatpatientswithrelapsedrefractorybreastcancer AT tzannouifigeneia multiantigentargetedtcelltherapytotreatpatientswithrelapsedrefractorybreastcancer AT velazquezyovana multiantigentargetedtcelltherapytotreatpatientswithrelapsedrefractorybreastcancer AT frenchkimmatthew multiantigentargetedtcelltherapytotreatpatientswithrelapsedrefractorybreastcancer AT leungwingchi multiantigentargetedtcelltherapytotreatpatientswithrelapsedrefractorybreastcancer AT lullasuhasini multiantigentargetedtcelltherapytotreatpatientswithrelapsedrefractorybreastcancer AT robertsoncatherine multiantigentargetedtcelltherapytotreatpatientswithrelapsedrefractorybreastcancer AT foremanclaudette multiantigentargetedtcelltherapytotreatpatientswithrelapsedrefractorybreastcancer AT wangtao multiantigentargetedtcelltherapytotreatpatientswithrelapsedrefractorybreastcancer AT bulsarashaun multiantigentargetedtcelltherapytotreatpatientswithrelapsedrefractorybreastcancer AT laptevanatalia multiantigentargetedtcelltherapytotreatpatientswithrelapsedrefractorybreastcancer AT grilleybambi multiantigentargetedtcelltherapytotreatpatientswithrelapsedrefractorybreastcancer AT ellismatthew multiantigentargetedtcelltherapytotreatpatientswithrelapsedrefractorybreastcancer AT osbornecharleskent multiantigentargetedtcelltherapytotreatpatientswithrelapsedrefractorybreastcancer AT coscioangela multiantigentargetedtcelltherapytotreatpatientswithrelapsedrefractorybreastcancer AT nangiajulie multiantigentargetedtcelltherapytotreatpatientswithrelapsedrefractorybreastcancer AT heslophelene multiantigentargetedtcelltherapytotreatpatientswithrelapsedrefractorybreastcancer AT rooneyclionam multiantigentargetedtcelltherapytotreatpatientswithrelapsedrefractorybreastcancer AT verajuanf multiantigentargetedtcelltherapytotreatpatientswithrelapsedrefractorybreastcancer AT lullapremal multiantigentargetedtcelltherapytotreatpatientswithrelapsedrefractorybreastcancer AT rimawimothaffar multiantigentargetedtcelltherapytotreatpatientswithrelapsedrefractorybreastcancer AT leenannm multiantigentargetedtcelltherapytotreatpatientswithrelapsedrefractorybreastcancer |